Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bottrop – page 19

1 691 clinical trials in Bottrop, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bottrop at a glance
1 691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 691 trials in Bottrop

Open in trial search

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5335
  • Sponsor:AstraZeneca AB

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

Dermatitis+2

Recruiting

A study to evaluate the effectiveness of NAV-240 in adults with moderate-to-severe hidradenitis suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IMB 101
  • Sponsor:Navigator Medicines Inc.

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

A study of ACR-368 and gemcitabine for patients with endometrial cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Acrivon Therapeutics Inc.

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Breast cancer

Recruiting

Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium acetate
  • Sponsor:Universitaet Muenster

Glioma

Recruiting

A study of ulixertinib, tovorafenib, and vinblastine sulfate for children with progressive, relapsed, or refractory low-grade glioma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Tovorafenib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study to evaluate the effect of upadacitinib on the frequency of eye inflammation in patients with axial spondyloarthritis.

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Care Arthritis Ltd.

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:WSG Women's Cancer Study Group GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bottrop

What the registry says about research in the country

01 Breast Cancer Research

Extensive clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments, evaluating innovative therapeutic approaches.

  • Early-stage breast cancer treatments
  • Metastatic disease management
  • Targeted therapy combinations

Studies include evaluation of novel drugs like ribociclib, elacestrant, and olaparib in combination with endocrine therapy.

02 Triple Negative Breast Cancer

Research investigating immunotherapy combinations and novel treatment approaches for patients with triple-negative breast cancer.

  • Post-surgery treatment optimization
  • Combination therapy assessment
  • Survival outcome improvements

Clinical trials evaluating sacituzumab govitecan-hziy with pembrolizumab versus standard treatments.

03 Ovarian Cancer Studies

Investigations into treatment strategies for advanced ovarian cancer, including peritoneal and fallopian tube cancers.

  • First-line therapy optimization
  • Combined treatment approaches
  • Progressive disease management

Focus on evaluating niraparib and bevacizumab combinations following chemotherapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.